ERRATUM article

Front. Pharmacol., 21 July 2022

Sec. Drugs Outcomes Research and Policies

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.972053

Erratum: Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019

This article is an erratum on:

  1. Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019

by Liu X-q, Wang X-y, Shen H-m, Pang W-y, Zhong M-k and Ma C-l (2022). Front. Pharmacol. 13:858139. doi: 10.3389/fphar.2022.858139

Due to a production error, Xiao-yu Wang was listed as the second author, instead of the co-first author.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: prescribing pattern, young-onset Parkinson’s disease, levodopa, dopamine agonist, levodopa equivalence daily dose

Citation: Frontiers Production Office (2022) Erratum: Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019. Front. Pharmacol. 13:972053. doi: 10.3389/fphar.2022.972053

Received: 17 June 2022; Accepted: 17 June 2022;
Published: 21 July 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.